New drug cocktail aims to boost pancreatic cancer surgery success

NCT ID NCT07436741

Recruiting now Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This Phase 3 trial tests whether adding the targeted drug surufatinib to standard chemotherapy before surgery helps more patients with high-risk pancreatic cancer have their tumors completely removed. About 106 adults with resectable or borderline resectable pancreatic cancer will be randomly assigned to receive either surufatinib plus chemo or chemo alone before and after surgery. The main goal is to see if the combination leads to a higher rate of clean surgical margins (R0 resection).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: surufatinib (a targeted cancer drug) combined with gemcitabine and nab-paclitaxel chemotherapy
What this could lead to: If successful, this could offer a more effective pre-surgery treatment to shrink pancreatic tumors, making complete removal more likely and potentially improving long-term outcomes.
What could go wrong: This is an early-stage Phase 3 trial with only 106 participants, so results may not apply to all patients. Adding surufatinib to chemo could increase side effects, and the treatment may not improve survival or cure the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm Pancreatic cancer, adult

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER, ADULT

Contacts and locations

Locations

Tianjin Medical University Cancer Institute and Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.